Targeting glioblastoma with advanced CAR-T cell therapy
Programming multi-pronged immune response to glioblastoma with IL-13Ra2/TGF-b CAR-T cell therapy.
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-11032840
This study is testing a new type of CAR-T cell therapy for people with glioblastoma, a tough brain cancer, to see if it can better target and attack the cancer cells while also helping the immune system fight back.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-11032840 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of CAR-T cell therapy specifically for glioblastoma, a highly aggressive brain cancer. The approach involves creating bispecific CAR-T cells that can recognize and attack glioblastoma cells while also modifying the tumor environment to enhance the immune response. By targeting the IL-13Rα2 antigen and transforming growth factor beta (TGF-β), the therapy aims to overcome the immunosuppressive barriers that limit the effectiveness of current treatments. Patients may have the opportunity to participate in trials that test this innovative therapy, which could lead to improved outcomes for those with glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded adequately to existing therapies.
Not a fit: Patients with other types of brain tumors or those who are not eligible for CAR-T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment responses for patients with glioblastoma.
How similar studies have performed: While CAR-T cell therapy has shown promise in other cancers, this specific approach targeting glioblastoma is novel and has not been extensively tested.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, YVONNE YU-HSUAN — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: CHEN, YVONNE YU-HSUAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer